Related Experiment Video
Updated: Mar 14, 2026
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.8K
Tyrosine Kinase Receptor Expression in Canine Liposarcoma
G Avallone1, V Pellegrino1, P Roccabianca2
11 Department of Veterinary Medical Sciences (DIMEVET), University di Bologna, Ozzano dell'Emilia, Italy.
Veterinary Pathology
|October 5, 2016
Summary
Tyrosine kinase receptor expression in canine liposarcoma was studied. High expression of FGF2, FGFR1, PDGFB, and PDGFRβ suggests PDGFRβ may be a target for canine cancer therapies.
Area of Science:
- Veterinary oncology
- Molecular pathology
- Cancer biology
Background:
- Tyrosine kinase receptors (TKRs) are crucial in cancer, serving as therapeutic targets.
- Limited data exists on TKR expression in canine liposarcoma (LP), a common soft tissue sarcoma.
- Understanding these pathways is key for developing targeted adjuvant therapies in veterinary medicine.
Purpose of the Study:
- To investigate the immunohistochemical expression of fibroblast growth factor receptor 1 (FGFR1), platelet-derived growth factor receptor-β (PDGFRβ), their ligands (FGF2, PDGFB), and c-kit in canine liposarcoma.
- To correlate TKR expression with tumor grade and proliferation markers.
- To identify potential therapeutic targets for canine LP.
Main Methods:
- Fifty canine liposarcoma samples were analyzed using immunohistochemistry.
- Expression levels of FGF2, FGFR1, PDGFB, PDGFRβ, and c-kit were categorized as high or low.
- Correlations between receptor expression, mitotic count, and MIB-1 proliferation index were assessed.
Main Results:
- High expression of FGF2 (62%), FGFR1 (68%), PDGFB (81.6%), and PDGFRβ (70.8%) was observed in canine LPs.
- c-kit expression was found in 12.5% of cases.
- Mitotic count negatively correlated with FGF2 and positively correlated with PDGFRβ expression.
Conclusions:
- The PDGFRβ-mediated pathway appears to play a role in canine liposarcoma progression.
- PDGFRβ represents a potential and promising target for novel adjuvant cancer therapies in dogs.
- Further research into TKR signaling pathways could improve treatment strategies for canine soft tissue sarcomas.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
01:26Receptor Tyrosine Kinases
20.3K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.3K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K